Fujifilm Toyama Chemical’s Favipiravir Shows some Promise in Japanese and Chinese COVID-19 Clinical Trials

Fujifilm Toyama Chemical’s Favipiravir Shows some Promise in Japanese and Chinese COVID-19 Clinical Trials

A drug called favipiravir, developed by a subsidiary of Fujifilm called Fujifilm Toyama Chemical, has generated encouraging outcomes based on clinical trials in Wuhan and Shenzhen involving 340 patients. The drug has been developed to address new strains of influenza.

Chinese Clinical Trials

Zhang Xinmin, an official with China’s science and technology ministry, reported that patients in Shenzhen participating in the clinical trial reported good outcomes for the virus after a median of four days after testing positive compared to a median of 11 days for those not treated with this drug, reported The Guardian. Moreover, patient X-rays showcased improvements in lung condition for about 91% of the patients taking favipiravir versus 62% of those not taking the drug.

The Drug Developer

Fujifilm Toyama Chemical developed the drug known as Avigan—in 2014, declined to comment on these claims coming out of China. However, their share price surged this morning by as much as 14.7%.

The Drug Shows Promise

Also called Avigan, it is an antiviral drug under development by Toyama Chemical of Japan with activity against many RNA viruses. By February 2020 the drug was being assess...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee